| Oct 14 |
DWTX: Virios Therapeutics Becomes Dogwood Therapeutics; Focus on Chemotherapy-Induced Neuropathic Pain…
|
| Oct 8 |
Virios Therapeutics Transforms into Dogwood Therapeutics
|
| Oct 7 |
Virios Therapeutics Enters Into Definitive Merger Agreement With Wex Pharmaceuticals
|
| Oct 7 |
Virios, and Wex Pharmaceuticals report business combination to form Dogwood Therapeutics
|
| Oct 7 |
Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”)
|
| Aug 13 |
VIRI: Enrollment Complete in Phase 2a Long COVID Trial; Results Expected in October 2024…
|
| Aug 9 |
Virios Therapeutics reports Q2 results
|
| Aug 8 |
Virios Therapeutics Announces Second Quarter 2024 Financial Results
|
| Aug 1 |
Virios Therapeutics to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024
|
| Jul 23 |
Virios Therapeutics Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne Center
|
